Group 1 - The core point of the article highlights that Tianzhihang-U experienced significant trading activity on January 7, with a total of 400,000 shares traded, amounting to 6.03 million yuan, at a price of 15.08 yuan, which represents a discount of 9.97% compared to the closing price of the day [2][3] - In the last three months, Tianzhihang-U has recorded a total of 27 block trades, with a cumulative transaction amount of 126 million yuan [3] - The stock closed at 16.75 yuan on the day of reporting, down 0.48%, with a turnover rate of 2.49% and a total trading volume of 189 million yuan, indicating a net outflow of 13.29 million yuan in main funds for the day [3] Group 2 - The latest margin financing balance for Tianzhihang-U is 222 million yuan, which has increased by 34.48 million yuan over the past five days, reflecting a growth rate of 18.35% [3] - Over the past five days, the stock has seen a cumulative increase of 12.34%, with a total net inflow of funds amounting to 542,400 yuan [3] - The block trades on January 7 involved two main brokerage firms, with institutional proprietary seats participating in two of the transactions, resulting in a net purchase of 4.01 million yuan [2][3]

亚辉龙公告称，其回复上交所问询函，与脑机星链拟合作产品未取得医疗器械注册证，最早2026年产生 收益。合作研发领域为非侵入式技术，尚处早期，预估投入3000万元左右。公司拟对脑机星链投资不超 1500万元。2025年前三季度，公司营收12.87亿元，同比降7.69%，净利润6042.09万元，同比降 72.36%，主因行业政策及交易性金融资产亏损。此外，1月6日股价异动，自查发现总裁办副主任姚兰 曾于1月5日卖出200股，与内幕信息无关。 ...

证券时报·数据宝统计显示，澳华内镜今日收盘价为46.48元，上涨2.18%，日换手率为1.98%，成交额为 1.23亿元，全天主力资金净流出623.78万元，近5日该股累计上涨7.10%，近5日资金合计净流入1418.39 万元。 两融数据显示，该股最新融资余额为1.25亿元，近5日增加309.36万元，增幅为2.54%。（数据宝） 1月7日澳华内镜大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 62.67 | 2679.77 | 42.76 | -8.00 | 机构专 | 中信证券股份有限公司上海浦东新 | | | | | | 用 | 区联洋证券营业部 | （文章来源：证券时报网） 澳华内镜1月7日大宗交易平台出现一笔成交，成交量62.67万股，成交金额2679.77万元，大宗交易成交 价为42.76元，相对今日收盘价折价8.00%。该笔交易的买方营业部为机构专用，卖方营业部为中信证券 股份有限公司 ...

资金流向方面，该股今日全天主力资金净流出2391.68万元。（数据宝） 麦澜德1月7日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 3191.21 | | 中信建投证券股份有限公司河北分公司 | 2204.94 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 2138.63 | | 机构专用 | 1958.92 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1161.81 | | 卖出营业部名称 | 卖出金额(万元) | | 机构专用 | 1848.78 | | 华泰证券股份有限公司总部 | 1626.55 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1544.43 | | 机构专用 | 1101.89 | | 国投证券股份有限公司广州猎德大道证券营业部 | 963.67 | （文章来源：证券时报网） 1月7日麦澜德（688273）收盘价54.86元，收盘下跌10.39%，全天换手率30.94%，振幅15.30%，成交额 6.31亿元。科创板交易公开信息显示，当日该股因日换手率达30%等上榜。 证券时 ...

精锋医疗此次发售2772.22万股，发行价43.24港元，募资总额12亿港元。 精锋医疗的基石投资者分别为中东资本ADIA、UBS AM Singapore、OrbiMed Genesis、腾讯旗下Huang River Investment、华夏基金（香港）、LYFE Capital Fund IV、大湾区共同家园投资、China Alpha、Tekful Limited （Cai Dong Chen）、ICSA、Sage Partners Master Fund、盘京基金、Infini，一共认购 7500万美元。 雷递网 雷建平 1月7日 深圳市精锋医疗科技股份有限公司（简称"精锋医疗"，股票代码："2675"）将于明日在港交所上市。 | | | | | 孜孜昌慎母胶变售胶仿43.24港元可异 | | | | --- | --- | --- | --- | --- | --- | --- | | | | 發售 | 假設超額配股 | | 假設超額配股權 | | | 基石投資者 | 認購金額 | 股份數目(1) | 權未獲行使 | | 獲悉數行使 | | | | | | | 佔已發行 | | 佔已發行 | | ...

证券日报网1月7日讯，爱迪特（301580）在接受调研者提问时表示，经过前期市场探索与交付体系完 善，公司3D打印材料和设备已通过一年的认证与市场检验，获得客户广泛认可，具备大规模推广的坚 实基础。公司有望通过3D打印技术和产品，联动种植、修复产品销售。公司3D打印增材制造技术逐步 成熟，是未来实现高效、高精度、低成本口腔诊疗闭环的核心技术。 ...

Core Viewpoint - Xinhua Medical (600587) announced that its rehabilitation product-related business will enter the industrialization phase by 2025, focusing on product promotion and market expansion [1] Group 1 - The company is set to begin industrialization of its rehabilitation products by 2025 [1] - The company will concentrate on promoting its products and expanding its market presence [1] - Specific operational data will be provided in future announcements [1]

证券日报网讯 1月7日，苏州高新（600736）在互动平台回答投资者提问时表示，根据景昱医疗官网资 料显示，景昱医疗聚焦脑科学领域，研发并提供脑机接口DBS产品。有关景昱医疗具体情况请直接咨询 该企业。 ...

Group 1 - The company Tianhua New Energy (300390) produces lithium battery materials, including battery-grade lithium hydroxide and lithium carbonate, primarily used in electric vehicle batteries, communication electronic power devices, and energy storage [1] - The company's anti-static ultra-clean technology products serve various industries, including semiconductor, storage, new display, communication, biomedicine, and precision manufacturing, providing essential cleanroom engineering design and production process static and micro-pollution protection [1] - Major clients of the company include AMD, Micron, Infineon, SMIC, Seagate, Western Digital, SAE, Great Wall Development, Sharp, Samsung, LGD, BOE, Huaxing Optoelectronics, and Tianma Microelectronics [1] Group 2 - The company also offers medical device products such as syringe-type/high-pressure injectors, self-destructing and safety syringes, as well as CT contrast injectors, medical CT tubes, and pulsed therapy devices [1]

Group 1 - The core viewpoint of the article is that Xinhua Medical (600587) acknowledges that its stock price fluctuations are influenced by multiple factors, including industry policies and market expectations [1] - The company emphasizes its strict adherence to information disclosure rules, asserting that there is no undisclosed information that should have been disclosed [1]